GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yu, Ji Hee | - |
dc.contributor.author | Park, So Young | - |
dc.contributor.author | Lee, Da Young | - |
dc.contributor.author | Kim, Nan Hee | - |
dc.contributor.author | Seo, Ji A. | - |
dc.date.accessioned | 2022-06-11T02:40:19Z | - |
dc.date.available | 2022-06-11T02:40:19Z | - |
dc.date.created | 2022-06-09 | - |
dc.date.issued | 2022-03 | - |
dc.identifier.issn | 2211-9132 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/141926 | - |
dc.description.abstract | With the emergence of various classes of blood glucose-lowering agents, choosing the appropriate drug for each patient is empha-sized in diabetes management. Among incretin-based drugs, glucagon-like peptide 1 (GLP-1) receptor agonists are a promising thera-peutic option for patients with diabetic kidney disease (DKD). Several cardiovascular outcome trials have demonstrated that GLP-1 receptor agonists have beneficial effects on cardiorenal outcomes beyond their blood glucose-lowering effects in patients with type 2 diabetes mellitus (T2DM). The renal protective effects of GLP-1 receptor agonists likely result from their direct actions on the kidney, in addition to their indirect actions that improve conventional risk factors for DKD, such as reducing blood glucose levels, blood pres-sure, and body weight. Inhibition of oxidative stress and inflammation and induction of natriuresis are major renoprotective mecha-nisms of GLP-1 analogues. Early evidence from the development of dual and triple combination agents suggests that GLP-1 receptor agonists will probably become popular treatment options for patients with T2DM. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC NEPHROLOGY | - |
dc.subject | GLUCAGON-LIKE PEPTIDE-1 | - |
dc.subject | DEPENDENT INSULINOTROPIC POLYPEPTIDE | - |
dc.subject | GASTRIC-INHIBITORY POLYPEPTIDE | - |
dc.subject | BROWN ADIPOSE-TISSUE | - |
dc.subject | CARDIOVASCULAR OUTCOMES | - |
dc.subject | FOOD-INTAKE | - |
dc.subject | COMBINATION THERAPY | - |
dc.subject | HEPATIC STEATOSIS | - |
dc.subject | OXIDATIVE STRESS | - |
dc.subject | IN-VITRO | - |
dc.title | GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yu, Ji Hee | - |
dc.identifier.doi | 10.23876/j.krcp.22.001 | - |
dc.identifier.scopusid | 2-s2.0-85127918075 | - |
dc.identifier.wosid | 000778371500002 | - |
dc.identifier.bibliographicCitation | KIDNEY RESEARCH AND CLINICAL PRACTICE, v.41, no.2, pp.136 - 149 | - |
dc.relation.isPartOf | KIDNEY RESEARCH AND CLINICAL PRACTICE | - |
dc.citation.title | KIDNEY RESEARCH AND CLINICAL PRACTICE | - |
dc.citation.volume | 41 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 136 | - |
dc.citation.endPage | 149 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002828722 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.subject.keywordPlus | GLUCAGON-LIKE PEPTIDE-1 | - |
dc.subject.keywordPlus | DEPENDENT INSULINOTROPIC POLYPEPTIDE | - |
dc.subject.keywordPlus | GASTRIC-INHIBITORY POLYPEPTIDE | - |
dc.subject.keywordPlus | BROWN ADIPOSE-TISSUE | - |
dc.subject.keywordPlus | CARDIOVASCULAR OUTCOMES | - |
dc.subject.keywordPlus | FOOD-INTAKE | - |
dc.subject.keywordPlus | COMBINATION THERAPY | - |
dc.subject.keywordPlus | HEPATIC STEATOSIS | - |
dc.subject.keywordPlus | OXIDATIVE STRESS | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordAuthor | Diabetic nephropathies | - |
dc.subject.keywordAuthor | Glucagon-like peptide 1 | - |
dc.subject.keywordAuthor | Type 2 diabetes mellitus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.